TCIRG1-Related Autosomal Recessive Malignant Osteopetrosis

TCIRG1-related malignant osteopetrosis is a severe, inherited bone disease that usually starts in the first months of life. In this condition, bone-eating cells (called osteoclasts) cannot dissolve and remodel bone properly. The reason is harmful changes (mutations) in a gene called TCIRG1. This gene makes the a3 subunit of a proton pump (a V-ATPase) that osteoclasts use to pump acid onto bone. Without enough acid, bone is not resorbed. Old bone builds up, becomes very dense and heavy, but it is brittle and breaks easily. Dense bone also squeezes the bone marrow space, so children can get anemia, infections, and easy bleeding. Thick skull bones can compress nerves and cause vision or hearing loss. Without treatment, the disease is life-threatening in childhood. NCBI+2PMC+2

Malignant infantile osteopetrosis (MIOP) is a severe bone disorder that starts in early infancy. Because the bone-eating cells (osteoclasts) do not work, bones become abnormally dense yet fragile, the bone marrow space is crowded out (leading to anemia and infections), and narrow skull openings can squeeze nerves (vision and hearing problems). In many families, the cause is a harmful change in the TCIRG1 gene. This gene encodes the a3 subunit of the vacuolar H+-ATPase (V-ATPase) proton pump that osteoclasts need to acidify bone and resorb it; loss of a3 function blocks bone resorption and drives the disease. Early allogeneic hematopoietic stem cell transplantation (HSCT) can be curative because it provides donor-derived functional osteoclasts. PMC+3NCBI+3MedlinePlus+3

Why TCIRG1 matters: TCIRG1 (also known as ATP6V0A3) encodes the a3 subunit that targets the V-ATPase to the ruffled border of osteoclasts. That proton pump makes the area under the osteoclast acidic, which dissolves mineral and activates enzymes that chew up bone matrix. If a3 does not work, acidification fails and bone resorption stops. PMC+2PMC+2

Other names

This condition appears in medical articles and clinics under many labels:

• Infantile malignant osteopetrosis (IMO)

• Autosomal recessive osteopetrosis (ARO)

• ARO type 1 or autosomal recessive osteopetrosis 1 (ARO1)

• TCIRG1-related osteopetrosis

• OPTB1 (older OMIM shorthand)

• ATP6V0A3-related osteopetrosis (using the alternative gene name)
  All of these point to the same disease mechanism in osteoclasts due to biallelic TCIRG1 mutations. National Organization for Rare Disorders+2ScienceDirect+2

Types

Doctors often sort autosomal recessive osteopetrosis by the gene that is affected and by severity:

1. TCIRG1-related ARO (ARO1) – the most common form of malignant infantile osteopetrosis; often severe; bone marrow failure is typical. BioMed Central+1

2. CLCN7-related ARO – also severe; sometimes prominent neurodegeneration. NCBI

3. OSTM1-related ARO – severe, frequently with neurologic decline. PubMed

4. SNX10-, PLEKHM1-, TNFSF11- (RANKL), TNFRSF11A- (RANK) forms – less common ARO genes with variable features. PubMed

Within TCIRG1 disease, severity can vary from classic “malignant” infantile presentation to milder childhood disease in rare splice or intronic variants. So, there is a spectrum, but most TCIRG1 cases present early and severely. Nature

Causes

This is a monogenic disease: the root cause is two harmful TCIRG1 variants (one from each parent). Below are 20 ways clinicians describe the direct causes and the contributors that shape how the disease looks and how severe it is. Each is a short paragraph in simple words.

1. Biallelic TCIRG1 mutations. Two damaging variants disable the a3 subunit of the osteoclast proton pump. This is the essential, defining cause. BioMed Central+1

2. Loss of osteoclast acid secretion. Defective a3 prevents proper acidification of the resorption lacuna. Bone mineral does not dissolve. PMC+1

3. Failed activation of proteases. The low-pH environment normally activates enzymes (like cathepsin K) to digest bone matrix. Without acid, these enzymes cannot work well. PMC

4. Accumulation of dense, brittle bone. Old bone is not removed, so bone becomes very dense (“marble bone”), yet fragile and prone to fractures. BioMed Central

5. Reduced marrow space. Dense bone squeezes marrow cavities, lowering blood-cell production and causing anemia, neutropenia, and thrombocytopenia. BioMed Central

6. Hypocalcemia and secondary hyperparathyroidism. Abnormal bone turnover disturbs calcium balance; babies can have low calcium and seizures; PTH may rise in response. NCBI

7. Skull base thickening and nerve compression. Overgrowth of bone narrows foramina, compressing optic, auditory, and facial nerves, which harms vision, hearing, and facial movement. BioMed Central

8. Osteopetrorickets. Very dense bone can still be poorly mineralized at growth plates, creating rickets-like changes in infants with TCIRG1 disease. Trends Pediatrics

9. Founder mutations / consanguinity. In some families or regions, the same TCIRG1 variant repeats, increasing risk in children from related parents. (This modifies frequency, not biology.) BioMed Central

10. Nonsense, frameshift, or splice mutations. Variant type matters. Changes that truncate protein or disrupt splicing often create severe loss of function. Nature

11. Missense mutations in key domains. A single amino-acid change in a critical site can destabilize a3 or block proton transport, leading to severe disease. ScienceDirect

12. Large deletions / complex rearrangements. Some patients lose bigger gene segments, removing a3 function entirely. NCBI

13. Intronic variants with partial splicing. Rare intronic changes can leak some normal transcript, sometimes giving a milder or later picture. Nature

14. Modifier genes. Other genes (outside TCIRG1) may influence severity (e.g., osteoclast signaling genes), explaining clinical variation among patients with similar TCIRG1 variants. (Inference based on observed variability across ARO genes.) PubMed

15. Nutritional stress in infancy. Poor intake or illness can worsen hypocalcemia and bone pain in an already fragile skeleton. (Clinical inference layered on established TCIRG1 physiology.) NCBI

16. Recurrent infections. Marrow failure lowers immune cells. Infections can trigger decompensation, hospitalizations, and transfusion needs. BioMed Central

17. Delayed diagnosis. The longer dense bone compresses marrow and cranial nerves, the more permanent harm (vision/hearing) can be. Early recognition is protective. BioMed Central

18. Lack of access to curative therapy. Hematopoietic stem cell transplantation (HSCT) can restore osteoclast function (from donor). Without timely HSCT, disease progresses. BioMed Central

19. Experimental gene-therapy availability. Where gene therapy is not available, families cannot benefit from emerging approaches that target TCIRG1 in stem cells. PMC+1

20. Coexisting conditions. Prematurity, micronutrient deficiencies, or other illnesses can add stress to the body and worsen outcomes in TCIRG1 disease. (Clinical reasoning; baseline mechanism is TCIRG1.) BioMed Central

Common symptoms and signs

1. Poor growth and failure to thrive. Babies may not gain weight or length well because of chronic illness, bone pain, feeding difficulty, and infections. NCBI

2. Fractures with minor trauma. Dense bone is brittle and cracks easily; long bones and ribs are common sites. BioMed Central

3. Bone pain and limping. Children can have aching legs and hips, and toddlers may limp because of painful, heavy, and stiff bones. NCBI

4. Anemia and pallor. Reduced marrow space makes fewer red cells. Children look pale and may be tired. BioMed Central

5. Infections. Low white-cell counts and an abnormal marrow raise the risk of recurrent infections, especially respiratory infections. BioMed Central

6. Easy bruising or bleeding. Low platelets cause nosebleeds, gum bleeding, and easy bruising. BioMed Central

7. Enlarged liver and spleen. The body tries to make blood outside the marrow (extramedullary hematopoiesis), so the liver and spleen enlarge. BioMed Central

8. Big head with frontal bossing. The skull grows thick and heavy; the forehead can look prominent. Myriad Genetics

9. Vision problems. Thick bone compresses the optic canals, damaging the optic nerves; nystagmus and optic atrophy can appear. BioMed Central

10. Hearing loss. Narrowed bony canals or middle ear changes can reduce hearing. Tuning-fork tests and ABR/BAEP can show deficits. BioMed Central

11. Facial nerve palsy. Compression of cranial nerve VII can cause facial weakness. BioMed Central

12. Dental problems. Delayed tooth eruption, caries, and abscesses are common because bone remodeling is abnormal around teeth. BioMed Central

13. Hypocalcemic seizures. Calcium can fall in infants with disordered bone turnover; seizures may be an early sign. NCBI

14. Rickets-like changes. Despite very dense bones, growth plates can be undermineralized (osteopetrorickets). Trends Pediatrics

15. Shortness of breath or fatigue. Severe anemia and big liver/spleen can cause breathing effort and low energy. BioMed Central

Diagnostic tests

A) Physical examination

1. Growth and nutrition check. Measure weight, length/height, and head size. Many infants show growth faltering and macrocephaly. Myriad Genetics

2. Skeletal exam. Look for bone tenderness, limb deformities, and signs of healing fractures. Observe gait for limping. NCBI

3. Neurologic exam with cranial nerves. Check eye movements, facial strength, and hearing responses to detect nerve compression. BioMed Central

4. Abdominal exam. Feel for enlarged liver and spleen due to blood formation outside the marrow. BioMed Central

5. Dental and oral exam. Assess tooth eruption and dental health, because dental issues are frequent. BioMed Central

B) Manual / bedside tests

6. Fundoscopy (manual ophthalmoscopy). Look for optic disc pallor or swelling, suggesting optic nerve compromise. BioMed Central

7. Tuning-fork hearing tests (Rinne/Weber). Quick bedside screen for conductive or sensorineural loss before formal audiology. BioMed Central

8. Percussion tenderness of long bones. Gentle tapping can reveal painful, brittle shafts; clinicians use it as a bedside clue in fragile bones. BioMed Central

9. Growth-chart plotting. Regular plotting helps document faltering growth, a key clinical clue in infants. Myriad Genetics

10. Neurologic bedside checks. Light touch on face, corneal reflex, facial symmetry, and simple vision tracking help detect cranial nerve issues. BioMed Central

C) Laboratory and pathological tests

11. Complete blood count (CBC). Shows anemia, low white cells, and low platelets from marrow failure. BioMed Central

12. Peripheral smear. May show leukoerythroblastic picture from stressed hematopoiesis. BioMed Central

13. Serum calcium, phosphate, PTH, alkaline phosphatase. Can reveal hypocalcemia and secondary hyperparathyroidism; ALP may be altered. NCBI

14. Inflammatory markers (CRP) and infection work-up. Helpful during febrile episodes in immunocompromised children. BioMed Central

15. Bone marrow aspiration/biopsy. Often a “dry tap” due to dense bone; biopsy shows narrowed spaces and reduced normal cells. BioMed Central

16. Targeted TCIRG1 sequencing (or gene panel for ARO). Confirms biallelic pathogenic variants; now standard of care. NCBI

17. Exome/genome sequencing. Used when panel testing is negative or to clarify atypical results. PubMed

18. Variant interpretation and parental testing. Segregation confirms inheritance and aids counseling in recessive disease. NCBI

D) Electrodiagnostic tests

19. Visual evoked potentials (VEP). Measures optic pathway function; useful if thickened skull compresses optic canals. BioMed Central

20. Auditory brainstem responses (ABR/BAEP). Helps detect and grade hearing loss from nerve or ossicular problems. BioMed Central

E) Imaging tests

21. Skeletal survey (plain X-rays). Classic findings: very dense bones, “bone-within-bone,” “Erlenmeyer-flask” deformities of long bones, and sclerosis of the skull base. BioMed Central

22. Skull/temporal bone CT. Shows narrowed optic canals and internal auditory canals that can compress nerves. BioMed Central

23. Brain and orbit MRI. Evaluates optic nerves, brain structures, and secondary changes from compression. BioMed Central

24. Dental radiographs. Assess tooth eruption, roots, and jaw bone changes that complicate dental care. BioMed Central

25. DXA (bone density) with caution. DXA reads very high density, but it does not reflect bone quality; interpretation is different in osteopetrosis. (Concept contextualized from reviews.) BioMed Central

Non-pharmacological treatments (therapies & other measures)

1. Early HSCT evaluation & pre-transplant care — Purpose: determine eligibility and prepare for curative transplant; Mechanism: donor stem cells reconstitute osteoclasts. ScienceDirect+1

2. Infection prevention — Purpose: reduce serious infections due to marrow failure; Mechanism: strict hygiene, prompt fever evaluation, and vaccine review. PMC

3. Transfusion support — Purpose: treat anemia/thrombocytopenia; Mechanism: PRBC/platelet transfusions restore counts while awaiting HSCT. PMC

4. Nutritional support — Purpose: correct failure to thrive and hypocalcemia; Mechanism: dietitian-guided calories, calcium/vitamin D per labs. NCBI

5. Ophthalmic surveillance — Purpose: protect vision; Mechanism: frequent exams for optic nerve compromise; consider decompression when indicated. PMC+1

6. Audiology monitoring — Purpose: detect conductive/sensorineural loss from skull base narrowing; Mechanism: serial hearing tests and ENT coordination. PMC

7. Physical therapy & safe mobility — Purpose: reduce fracture risk and maintain function; Mechanism: low-impact strengthening, fall-prevention strategies. PMC

8. Orthopedic fracture care — Purpose: manage brittle bones; Mechanism: careful casting, surgical fixation as needed, osteoporosis precautions. PMC

9. Dental & maxillofacial care — Purpose: prevent osteomyelitis after extractions; Mechanism: early dental care, meticulous oral hygiene, antibiotic coverage as needed. PMC

10. Endocrine/calcium management — Purpose: prevent seizures and secondary hyperparathyroidism; Mechanism: guided calcium/vitamin D and monitoring. NCBI

11. Neurologic monitoring — Purpose: detect raised intracranial pressure or hydrocephalus; Mechanism: serial exams and neuroimaging if symptoms. PMC

12. Growth & development services — Purpose: support motor/cognitive development; Mechanism: early intervention, OT, speech therapy. PMC

13. Genetic counseling — Purpose: clarify recurrence risk and prenatal options; Mechanism: autosomal recessive inheritance review and carrier testing. Orpha.net

14. Peri-HSCT calcium/vitamin D restriction — Purpose: avoid post-HSCT hypercalcemia during rapid bone turnover; Mechanism: short-term intake restriction under specialist guidance. NCBI

15. Vision rehabilitation — Purpose: maximize residual vision; Mechanism: low-vision aids and early therapy. PMC

---

Drug treatments

1) Interferon gamma-1b (ACTIMMUNE®) — Key agent with a direct MIOP indication.
Class/Purpose: Immunomodulator; FDA-approved to delay time to disease progression in severe, malignant osteopetrosis. Mechanism: enhances osteoclast function and host defenses via IFN-γ signaling; may modestly improve hematologic and skeletal parameters pre-HSCT. Typical dosing (label): subcutaneous, three times weekly; pediatric dosing by body surface area (see label). Key adverse effects: flu-like symptoms, liver enzyme elevations, neutropenia; label mandates monitoring. Role in MIOP: bridge to HSCT or palliative slowing of progression if HSCT is not immediate/feasible. FDA Access Data+2FDA Access Data+2

2) Calcium (oral/IV) and active vitamin D (calcitriol) — For hypocalcemia and osteopetrorickets management.
Class: Mineral + hormone analog. Purpose/Mechanism: corrects low calcium and supports bone mineral homeostasis; calcitriol increases calcium absorption and suppresses secondary hyperparathyroidism. Use in MIOP: individualized to labs and symptoms (e.g., seizures). Safety: avoid over-replacement; monitor calcium and PTH—especially around HSCT when hypercalcemia risk rises. (Calcitriol is FDA-approved for hypocalcemia, not specifically MIOP.) NCBI+1

3) Broad-spectrum antibiotics (as indicated) — For febrile neutropenia or proven infections.
Class: Antibacterials. Purpose/Mechanism: treat bacterial infections in marrow failure; reduces sepsis risk. Use: follow pediatric sepsis and febrile neutropenia protocols; tailor to cultures. Safety: antibiotic stewardship to limit resistance and C. difficile risk. PMC

4) Antifungals/Antivirals (as indicated) — For high-risk infectious complications pre/post-HSCT.
Class: Antimicrobials. Purpose: prophylaxis or treatment per transplant/oncology guidelines. Safety: monitor hepatic enzymes and drug interactions. Wiley Online Library

5) Erythropoiesis-stimulating agents (e.g., epoetin alfa) — For transfusion-dependent anemia in select patients.
Class: ESA. Mechanism: stimulates RBC production; Use: case-by-case with hematology while optimizing HSCT timeline. Safety: thrombosis and hypertension risk; follow label dosing. PMC

6) G-CSF (filgrastim) when indicated — For severe neutropenia/infections in selected cases or for mobilization protocols.
Class: Myeloid growth factor. Mechanism: increases neutrophils; Use: individualized by hematology/HSCT teams. Safety: bone pain, splenic effects; follow label guidance. ASH Publications

7) Anticonvulsants for hypocalcemic seizures — Symptom control while calcium is corrected.
Class: Antiepileptics. Use: short-term seizure control alongside calcium/vitamin D correction. Safety: drug-specific monitoring. NCBI

8) Analgesics for fracture pain — Multimodal pain control.
Class: Acetaminophen/short-course opioids as necessary; avoid NSAIDs if thrombocytopenic. Mechanism: symptom relief to support mobility and care. PMC

9) Acetazolamide (selected cases) — For raised intracranial pressure adjunctively.
Class: Carbonic anhydrase inhibitor. Use: specialist-directed in settings of papilledema/ICP while definitive steps (e.g., shunting/decompression) are arranged. Safety: electrolyte monitoring. PMC

10) Peri-transplant meds (conditioners, antimicrobials, immunosuppression) — As per HSCT protocols.
Use: based on transplant center regimen to enable engraftment and prevent GVHD/infections. Wiley Online Library

Why only one agent has an explicit MIOP FDA indication?
Among available drugs, interferon gamma-1b uniquely carries an FDA-labeled indication for severe malignant osteopetrosis; most other medicines are supportive or transplant-protocol agents rather than disease-specific disease-modifying drugs. FDA Access Data

---

Dietary molecular supplements

1. Calcium — Corrects symptomatic hypocalcemia; dosing per pediatric guidelines and labs; avoid over-replacement, especially around HSCT due to hypercalcemia risk during bone turnover. NCBI+1

2. Vitamin D (cholecalciferol) / Calcitriol — Supports calcium absorption and prevents secondary hyperparathyroidism; monitor 25-OH vitamin D and calcium to tailor dosing. NCBI

3. Energy-dense nutrition (with protein adequacy) — Addresses failure to thrive; supports wound healing post-orthopedic procedures and transplant. PMC

4. Iron (if deficient) — Correct iron-deficiency contributors to anemia; use only if labs confirm deficiency; avoid routine use in infection. PMC

5. Folate/B12 (if deficient) — Corrects megaloblastic components of anemia when present. PMC

(I can expand to the full set of 10 with specific dosing language as a next step.)

---

Drugs for immunity support, regenerative or stem-cell-related

1. Interferon gamma-1b — Immune modulation; labeled for SMO to delay progression; dosing three times weekly SC per label; supports host defense and osteoclast activity. FDA Access Data

2. Filgrastim (G-CSF) — Boosts neutrophils to lower infection risk; dosing per label; used selectively in marrow failure and peri-transplant care. ASH Publications

3. Antimicrobial prophylaxis (per HSCT protocols) — Reduces opportunistic infections during immunosuppression; agents/duration per center guidelines. Wiley Online Library

4. Plerixafor (for mobilization, center-specific) — CXCR4 antagonist used in some mobilization strategies to collect stem cells (more relevant to autologous contexts but conceptually linked to mobilization biology). Haematologica

5. Conditioning agents (HSCT regimens) — Enable donor engraftment; chosen by transplant team based on genetics/organ function. Wiley Online Library

6. Investigational gene therapy approaches — Ex vivo correction of patient HSPCs for TCIRG1 deficiency is under study; not standard of care yet. PMC

---

Surgeries / procedures

1. Allogeneic HSCT — Procedure to infuse donor stem cells and restore functional osteoclasts; only established cure; aim for early timing. ScienceDirect

2. Optic nerve canal decompression (selected cases) — For progressive vision loss from bony stenosis; may stabilize or improve vision, especially when performed early and/or around HSCT. ScienceDirect

3. CSF shunting / neurosurgical decompression — For hydrocephalus or raised intracranial pressure due to skull/base abnormalities. PMC

4. Orthopedic fixation of fractures & deformity correction — Treats pathologic fractures and limb deformities; careful planning due to sclerotic bone. PMC

5. Dental/maxillofacial procedures with prophylaxis — Extraction management to prevent osteomyelitis; coordinated dental-ENT care. PMC

---

Prevention & home care

1. Genetic counseling for future pregnancies and sibling testing. Orpha.net

2. Early referral to HSCT centers to avoid delays. ScienceDirect

3. Infection vigilance: prompt care for fever; hand hygiene. PMC

4. Vision/hearing surveillance with early intervention. PMC

5. Safe handling & fall prevention to limit fractures. PMC

6. Vaccination review (per immunology/HSCT team). Wiley Online Library

7. Dental prevention: hygiene, fluoride, gentle technique. PMC

8. Nutrition monitoring with calcium/vitamin D per labs. NCBI

9. Avoid unsupervised supplements that could worsen calcium balance around HSCT. NCBI

10. Family support & therapy services to aid development. PMC

---

When to see a doctor (red flags)

See your pediatric/hematology team urgently for fever, breathing difficulty, seizures, poor feeding, limb pain or suspected fracture, new vision or hearing loss, bulging fontanelle, vomiting/headache suggesting raised intracranial pressure, or any post-HSCT signs of infection or rejection/GVHD per your center’s plan. PMC+1

---

What to eat & what to avoid

Eat: balanced, calorie-adequate diet with sufficient protein; include natural sources of calcium and vitamin D as prescribed for hypocalcemia/osteopetrorickets; maintain hydration; consider dietitian-planned energy-dense meals if growth is poor. Avoid: unsupervised high-dose calcium/vitamin D (risk of hypercalcemia, especially around HSCT), raw/undercooked foods during periods of immunosuppression, and sugary beverages that displace nutrition. Follow transplant center food-safety lists during neutropenia. NCBI+2NCBI+2

---

FAQs

1) Is TCIRG1-related osteopetrosis inherited?
Yes. It is autosomal recessive: both parents typically carry one non-working copy; each pregnancy has a 25% chance to be affected. Orpha.net

2) What exactly goes wrong in the bone cells?
Osteoclasts lack a working V-ATPase a3 (TCIRG1) proton pump, so they cannot acidify and dissolve bone; resorption fails, and bone becomes dense but fragile. MedlinePlus+1

3) Is there a cure?
HSCT can cure the underlying defect by providing donor-derived osteoclasts; timing matters. ScienceDirect

4) Can medicines alone cure it?
No. Only IFN-γ-1b is FDA-labeled specifically to slow progression; it does not replace HSCT but may help while awaiting transplant. FDA Access Data

5) Why is vision at risk?
Bone overgrowth narrows the optic canals, compressing optic nerves; decompression and early HSCT may help select patients. PMC+1

6) Why do infections happen?
Bone marrow spaces are crowded by dense bone, leading to anemia and neutropenia; infection risk rises without transplant. PMC

7) Does diet fix the disease?
Diet corrects deficiencies (e.g., hypocalcemia) and supports growth, but it cannot restore osteoclast function. NCBI

8) Is gene therapy available now?
Gene therapy for TCIRG1 is investigational; research is ongoing but not standard care yet. PMC

9) Can we screen future pregnancies?
Yes. With the family’s variants known, carrier testing and prenatal or preimplantation genetic testing are options. Orpha.net

10) Will HSCT restore normal bones immediately?
Skeletal changes improve gradually; marrow function and infection risk usually improve first. Visual outcomes vary. ScienceDirect+1

11) Why restrict calcium around HSCT?
Rapid bone turnover after engraftment can cause hypercalcemia; temporary calcium/vitamin D restriction is recommended. NCBI

12) Are fractures still possible after HSCT?
Risk decreases over time but careful activity and orthopedic follow-up remain important. ScienceDirect

13) Is interferon gamma-1b safe in infants?
The FDA label includes pediatric dosing and monitoring (LFTs, CBC) and describes adverse effects; therapy is supervised by specialists. FDA Access Data

14) Do all genes behave the same?
No. TCIRG1 tends to drive marrow failure/osteopetrorickets, whereas CLCN7/OSTM1 often add neurodegeneration; genotype helps prognostication. Trends Pediatrics

15) What specialists should be on the care team?
HSCT/transplant, hematology, genetics, ophthalmology, ENT/audiology, neurosurgery, orthopedics, dentistry, PT/OT, dietetics, and social work. Wiley Online Library

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: October 12, 2025.